Cardiogen 20mg (Bioregulator)

Cardiogen

Cardiogen is a short peptide with known properties as a bioregulator. Research shows that its primary effects are on fibroblasts, the cells responsible for tissue repair and scar formation throughout the body. Though the focus on cardiogen has been on its role in a variety of cardiovascular diseases (hence the name), research shows that its ability to alter fibroblast activity has potential benefits in a variety of tissues. In addition, cardiogen appears to by a synergistic peptide, enhancing the benefit of certain standard therapies and thereby improving long-term outcomes while reducing side effects. Finally, preliminary research in rat models suggests that cardiogen may increase rates of apoptosis in tumor cells.

Cardiogen and the Heart

In the heart, cardiogen appears to stimulate cardiomyocyte proliferation while reducing fibroblast growth and development. This leads to decreased scar formation and improved long-term outcomes in regards to cardiac remodeling leading to heart failure. Additionally, it appears that cardiogen 20mg can decrease p53 protein expression and thereby diminish rates of apoptosis[1].

Cardiogen and Cancer

Even though cardiogen reduces apoptosis in heart cells by down-regulating p53 expression, it may have the opposite effect in tumor cells. Research in rat models of M-1 sarcoma shows that apoptosis levels are higher in the tumor cells following cardiogen administration. What is more, the effect is does-dependent, indicating that the biological effect is real[2]. The peptide appears to enhance apoptosis in tumor cells and may be somewhat selective for tumor cells due to their enhanced and unusual vascular supply. This may make cardiogen a targeted treatment for at least some types of cancer. In addition, if the peptide enhances the action of standard cancer treatments (as it does in heart disease treatment), then it may prove a very potent addition to the arsenal of cancer fighters.

Doctors Levdik and Knyazkin, both of whom have worked in some capacity with Vladimir Khavinson through the St. Petersburg Institute of Bioregulation and Gerontology and the Russian Academy of Medical Sciences, have extensive experience researching the impact of amino acids and short peptides on both cancer and healthy tissues as they become dysfunctional and precancerous. Their work with Cardiogen 20mg has positioned it as the next possible candidate for approval, in Russia, for the treatment of sarcoma.

Cardiogen 20mg and the Prostate

Research in tissue cultures shows that cardiogen, along with several similar peptides, alters the expression of signaling factors in fibroblasts of the prostate. Levels of these signaling factors are important in establishing favorable a microenvironment within tumors and may contribute to both the development and progression of prostate cancer. Solid evidence shows that the synthesis of these markers is substantially altered in aging and senescent fibroblasts, which may explain why prostate cancer is almost ubiquitous in older men but nearly unheard of in younger men[3]. In fact, studies show that cardiogen can normalize levels of these signaling molecules to match or even improve upon what is seen in young cell cultures, suggesting that cardiogen may be effective both in preventing prostate cancer and in controlling its progression once it develops[4].

Cardiogen Summary

Cardiogen 20mg, while less researched than some other bioregulators, appears to have potent effects on multiple body tissues including the heart and prostate. Additionally, the peptide may be beneficial in the treatment of certain types of cancer, particularly sarcoma. Currently, the biggest benefits of cardiogen appear to be in the settings of heart attack, hypertension, and chronic heart failure where the peptide not only offers benefits of its own accord, but acts in a synergistic manner with established treatments.

Cardiogen exhibits minimal side effects, good oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Cardiogen for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy Cardiogen if you are a licensed researcher.

Storage Instructions:

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping 3-4 months reconstituted (mixed with bacteriostatic water) to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.

Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.

Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.

However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.